Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Summary

Phase 2 study of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa

Timeline

Start

2018-12-21

Primary completion

2021-01-14

Completion

2021-03-09

Outcome

Missed primary endpoint

registry analysis (other test); Placebo vs Avacopan 10 mg; p = 0.1321; % Difference (Avacopan - Placebo) -8.4 (95% CI -18.7 to 2.4) NCT03852472 ↗

registry analysis (other test); Placebo vs Avacopan 30 mg; p = 0.4503; % Difference (Avacopan - Placebo) 4.3 (95% CI -6.9 to 15.5) NCT03852472 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avacopan	Small molecule	10 mg	—
Subject	Avacopan	Small molecule	30 mg	—

Indications